Summary
770.69 -16.33(-2.07%)05/16/2024
Lilly(Eli) & Co (LLY)
Lilly(Eli) & Co (LLY)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.43 | -0.46 | 0.06 | 7.22 | 29.83 | 80.86 | 629.27 | 85,534.43 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 777.48 | |
| Open | 768.90 | |
| High | 779.09 | |
| Low | 762.16 | |
| Volume | 2,344,634 | |
| Change | 10.93 | |
| Change % | 1.43 | |
| Avg Volume (20 Days) | 2,686,070 | |
| Volume/Avg Volume (20 Days) Ratio | 0.87 | |
| 52 Week Range | 419.80 - 800.78 | |
| Price vs 52 Week High | -2.91% | |
| Price vs 52 Week Low | 85.20% | |
| Range | 1.12 | |
| Gap Up/Down | 1.92 | |
Fundamentals | ||
| Market Capitalization (Mln) | 736,564 | |
| EBIDTA | 13,373,700,096 | |
| PE Ratio | 112.4260 | |
| PEG Ratio | 1.4311 | |
| WallStreet Target Price | 856.61 | |
| Book Value | 14.2290 | |
| Earnings Per Share | 6.7600 | |
| EPS Estimate Current Quarter | 2.4600 | |
| EPS Estimate Next Quarter | 2.7700 | |
| EPS Estimate Current Year | 13.8000 | |
| EPS Estimate Next Year | 19.4800 | |
| Diluted EPS (TTM) | 6.7600 | |
| Revenues | ||
| Profit Marging | 0.1708 | |
| Operating Marging (TTM) | 0.3120 | |
| Return on asset (TTM) | 0.1260 | |
| Return on equity (TTM) | 0.5075 | |
| Revenue TTM | 35,932,098,560 | |
| Revenue per share TTM | 39.9190 | |
| Quarterly Revenue Growth (YOY) | 0.2600 | |
| Quarterly Earnings Growth (YOY) | 0.6640 | |
| Gross Profit (TTM) | 21,911,600,000 | |
| Dividends | ||
| Dividend Share | 4.6900 | |
| Dividend Yield | 0.0068 | |
| Valuations | ||
| Trailing PE | 112.4260 | |
| Forward PE | 60.2410 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 66.3424 | |
| Revenue Enterprise Value | 21.5956 | |
| EBITDA Enterprise Value | 86.0117 | |
| Shares | ||
| Shares Outstanding | 950,404,992 | |
| Shares Float | 898,100,348 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.16 | |
| Institutions (%) | 84.57 | |
05/16 17:11 EST - zacks.com
3 Stocks to Buy Following Positive Earnings Results
All three of these companies saw buyers step up post-earnings, reflecting the positivity of their results.
3 Stocks to Buy Following Positive Earnings Results
All three of these companies saw buyers step up post-earnings, reflecting the positivity of their results.
05/16 11:15 EST - zacks.com
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.
05/16 08:13 EST - investorplace.com
The Dividend Investor's Playbook: 3 Stocks for Consistent Cash Flow in 2024
If you are looking for dividend stocks to buy, you're at the right place; research shows that companies regularly raising payouts, known as “dividend growers,” boast compound annual returns of about 11.7% from 1986 to 2016. Even companies paying dividends but not raising them earned an average of 9.9% per year.
The Dividend Investor's Playbook: 3 Stocks for Consistent Cash Flow in 2024
If you are looking for dividend stocks to buy, you're at the right place; research shows that companies regularly raising payouts, known as “dividend growers,” boast compound annual returns of about 11.7% from 1986 to 2016. Even companies paying dividends but not raising them earned an average of 9.9% per year.
05/16 08:00 EST - globenewswire.com
Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly
Collaboration leverages Totus' covalent chemistry-based OmniDEL platform for the identification of small molecule drug candidates across multiple therapeutic areas Collaboration leverages Totus' covalent chemistry-based OmniDEL platform for the identification of small molecule drug candidates across multiple therapeutic areas
Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly
Collaboration leverages Totus' covalent chemistry-based OmniDEL platform for the identification of small molecule drug candidates across multiple therapeutic areas Collaboration leverages Totus' covalent chemistry-based OmniDEL platform for the identification of small molecule drug candidates across multiple therapeutic areas
05/16 07:15 EST - investorplace.com
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks?
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks?
05/16 07:15 EST - fool.com
These 2 No-Brainer Growth Stocks Are Breaking New Ground
Eli Lilly and Regeneron are developing competing hearing-loss gene therapies. These drugmakers have solid businesses thanks to their innovative qualities.
These 2 No-Brainer Growth Stocks Are Breaking New Ground
Eli Lilly and Regeneron are developing competing hearing-loss gene therapies. These drugmakers have solid businesses thanks to their innovative qualities.
05/16 06:56 EST - reuters.com
Lilly's weekly insulin succeeds in late-stage studies
Eli Lilly said on Thursday that its once-weekly insulin efsitora met the main goals in two late-stage trials evaluating it in people with type 2 diabetes.
Lilly's weekly insulin succeeds in late-stage studies
Eli Lilly said on Thursday that its once-weekly insulin efsitora met the main goals in two late-stage trials evaluating it in people with type 2 diabetes.
05/16 06:45 EST - prnewswire.com
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes Efsitora was equally safe and effective among adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists INDIANAPOLIS , May 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections. In the treat-to-target clinical trials, efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally.
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes Efsitora was equally safe and effective among adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists INDIANAPOLIS , May 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections. In the treat-to-target clinical trials, efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally.
05/15 13:09 EST - investorplace.com
Wall Street Favorites: 3 Growth Stocks With Strong Buy Ratings for May 2024
If you think you've missed the rally in high-flying growth stocks, think again. Even though the market is close to all-time highs, many well-known growth stocks still have plenty of room to run.
Wall Street Favorites: 3 Growth Stocks With Strong Buy Ratings for May 2024
If you think you've missed the rally in high-flying growth stocks, think again. Even though the market is close to all-time highs, many well-known growth stocks still have plenty of room to run.
05/15 11:38 EST - youtube.com
Bullish On TOST & LLY
Should traders remain bullish with the current macro environment? Tom Plumb says that a good sustainable business plan, good people, disciplined allocation of capital, high return on capital, and profit margins that reflect disciplined execution in markets, are where your value-added is rewarded.
Bullish On TOST & LLY
Should traders remain bullish with the current macro environment? Tom Plumb says that a good sustainable business plan, good people, disciplined allocation of capital, high return on capital, and profit margins that reflect disciplined execution in markets, are where your value-added is rewarded.
05/15 11:00 EST - forbes.com
How Are Eli Lilly's Profit Margins Trending?
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development expenses (IPR&D).
How Are Eli Lilly's Profit Margins Trending?
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development expenses (IPR&D).
05/15 10:56 EST - zacks.com
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.
05/15 10:52 EST - reuters.com
UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down
Britain's Pharmacy2U said on Wednesday it had cut the prices of weight-loss medication Wegovy and Mounjaro, becoming the latest in a slew of online pharmacies and slimming clinics to do so as initial supply shortages of the drugs ease in the country.
UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down
Britain's Pharmacy2U said on Wednesday it had cut the prices of weight-loss medication Wegovy and Mounjaro, becoming the latest in a slew of online pharmacies and slimming clinics to do so as initial supply shortages of the drugs ease in the country.
05/15 08:00 EST - prnewswire.com
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
INDIANAPOLIS , May 15, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and compliance officer, and a member of Lilly's Executive Committee, will retire after 27 years of service with the company, effective Dec. 31, 2024. Weems will continue to serve in his role while the company conducts an internal and external search for a chief ethics and compliance officer.
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
INDIANAPOLIS , May 15, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and compliance officer, and a member of Lilly's Executive Committee, will retire after 27 years of service with the company, effective Dec. 31, 2024. Weems will continue to serve in his role while the company conducts an internal and external search for a chief ethics and compliance officer.
05/15 05:44 EST - fool.com
These 2 Words Explain Why Eli Lilly Stock Is a Buy Right Now
Eli Lilly's top line is expanding quickly for such a large business. Two closely related drugs are to credit for much of the growth.
These 2 Words Explain Why Eli Lilly Stock Is a Buy Right Now
Eli Lilly's top line is expanding quickly for such a large business. Two closely related drugs are to credit for much of the growth.
05/14 17:58 EST - reuters.com
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs
Eli Lilly has entered into a settlement deal with a medi spa that had sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, the drugmaker said on Tuesday.
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs
Eli Lilly has entered into a settlement deal with a medi spa that had sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, the drugmaker said on Tuesday.
05/14 14:35 EST - cnbc.com
Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey says
A wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind's new AI model can predict the structure of molecules.
Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey says
A wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind's new AI model can predict the structure of molecules.
05/14 09:53 EST - fool.com
2 Top Pharma Stocks That Just Keep Getting Better and Better
Eli Lilly and Novo Nordisk are competing in treating diabetes and obesity. Both have launched successful products in these two markets.
2 Top Pharma Stocks That Just Keep Getting Better and Better
Eli Lilly and Novo Nordisk are competing in treating diabetes and obesity. Both have launched successful products in these two markets.
05/14 07:30 EST - fool.com
Is Eli Lilly's Latest Deal a Gamechanger?
Demand for weight-loss medications such as Ozempic and Mounjaro is soaring. Eli Lilly, the developer of Mounjaro and Zepbound, is investing heavily to meet demand.
Is Eli Lilly's Latest Deal a Gamechanger?
Demand for weight-loss medications such as Ozempic and Mounjaro is soaring. Eli Lilly, the developer of Mounjaro and Zepbound, is investing heavily to meet demand.
05/14 06:30 EST - investorplace.com
Biotech Behemoths: 3 Giants Set to Dominate the Health Scene
Biotechnology is an interesting place to look if you're looking for growth and are not put off by severe levels of volatility. Undoubtedly, there's a bit of speculative zest regarding some of the smaller biotech stocks out there, many of whom depend on just a handful of pipeline candidates.
Biotech Behemoths: 3 Giants Set to Dominate the Health Scene
Biotechnology is an interesting place to look if you're looking for growth and are not put off by severe levels of volatility. Undoubtedly, there's a bit of speculative zest regarding some of the smaller biotech stocks out there, many of whom depend on just a handful of pipeline candidates.